A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects

Boryung

Status and phase: Completed; Phase 1

Conditions: Hypertension; Diabetes Mellitus, Type 2

Treatments: Drug: BR1019-1; Drug: BR1019-2; Drug: BR1019-1 + BR1019-2

Study type: Interventional

Funder types: Industry

Identifiers

NCT05875259

BR-FDC-CT-101

Details and patient eligibility

About

The purpose of this study is to evaluate the pharmacokinetic interaction and safety between BR1019-1 and BR1019-2 in healthy adult subjects.

Enrollment: 36 patients

Sex: All

Ages: 19 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adults aged 19 to 55 years at screening
• Those who voluntarily decide to participate in the study and provide written consent to follow the study directions after listening to and fully understanding the detailed explanation on this study

Exclusion criteria

• Those who have clinically significant diseases associated with the cardiovascular system, respiratory system, liver, kidney, nervous system, endocrine system, blood/tumor, psychiatric disorders, or urinary system, as well as drug abuse, or a history thereof.

• Those who took any prescription drugs or herbal medicines within 14 days prior to the first day of administration or any over-the-counter (OTC) drugs within 7 days prior to the first day of administration (however, if other conditions are appropriate according to the judgment of the investigator, they may participate in the clinical study.)

• Those who took drugs inducing and inhibiting drug-metabolizing enzymes, such as barbiturates, within 30 days prior to the study initiation.

• Those who have been on a diet (especially grapefruit juice or its products) that may affect the absorption, distribution, metabolism, and excretion of the drug within 7 days prior to the first day of administration.

• Pregnant women, potentially pregnant women, or breast-feeding women Those who do not agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using medically acceptable methods of contraception* throughout the entire period from the date of the first administration of the investigational product to the end of the clinical study

  • Medically acceptable methods of contraception: Combined use of intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used

• Those who are unwilling or unable to comply with the dietary and lifestyle guidelines required for the clinical study

• Those who have clinically significant abnormalities in the results of other clinical laboratory tests or who have been determined by the investigator to be ineligible to participate in the clinical study due to other reasons (e.g., non-compliance with instructions, uncooperative attitude, etc.)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

36 participants in 6 patient groups

Sequence 1

Experimental group

Description:

The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. \*sequence 1: A-B-C

Treatment:

Drug: BR1019-1 + BR1019-2

Drug: BR1019-1

Drug: BR1019-2

Sequence 2

Experimental group

Description:

The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. \*sequence 2: A-C-B

Treatment:

Drug: BR1019-1 + BR1019-2

Drug: BR1019-1

Drug: BR1019-2

Sequence 3

Experimental group

Description:

The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. \*sequence 3: B-A-C

Treatment:

Drug: BR1019-1 + BR1019-2

Drug: BR1019-1

Drug: BR1019-2

Sequence 4

Experimental group

Description:

The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. \*sequence 4: B-C-A

Treatment:

Drug: BR1019-1 + BR1019-2

Drug: BR1019-1

Drug: BR1019-2

Sequence 5

Experimental group

Description:

The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. \*sequence 5: C-A-B

Treatment:

Drug: BR1019-1 + BR1019-2

Drug: BR1019-1

Drug: BR1019-2

Sequence 6

Experimental group

Description:

The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. \*sequence 6: C-B-A

Treatment:

Drug: BR1019-1 + BR1019-2

Drug: BR1019-1

Drug: BR1019-2